In a cohort receiving chemotherapy of atezolizumab plus bevacizumab, 30% reduction was an independent predictor of objective response (odds ratio: 5.517; p = 0.003) in HCC with baseline AFP ≥ 20 ng/mL [18]. The gene discussed is AFP; the disease is hepatocellular carcinoma.